New hope for Tough-to-Treat colon cancer patients
NCT ID NCT07362836
Summary
This study compares two different drug combinations for people with advanced colorectal cancer that has spread and has a specific genetic change (RAS mutation). About 224 patients whose cancer has worsened after initial treatment will receive either a newer drug (fruquintinib) plus chemotherapy or the current standard treatment (bevacizumab plus chemotherapy). Researchers want to see which approach better controls cancer growth and extends survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.